Exploring the potential of Claude 2 for risk of bias assessment: Using a large language model to assess randomized controlled trials with RoB 2
View ORCID ProfileAngelika Eisele-Metzger, View ORCID ProfileJudith-Lisa Lieberum, View ORCID ProfileMarkus Toews, View ORCID ProfileWaldemar Siemens, View ORCID ProfileFelix Heilmeyer, Christian Haverkamp, View ORCID ProfileDaniel Boehringer, View ORCID ProfileJoerg J Meerpohl
doi: https://doi.org/10.1101/2024.07.16.24310483
Angelika Eisele-Metzger
1Institute for Evidence in Medicine, Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg, Germany
2Cochrane Germany, Cochrane Germany Foundation, Freiburg, Germany
Judith-Lisa Lieberum
3Eye Center, Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg, Germany
Markus Toews
1Institute for Evidence in Medicine, Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg, Germany
Waldemar Siemens
1Institute for Evidence in Medicine, Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg, Germany
Felix Heilmeyer
4Institute for Digitalization in Medicine, Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg, Germany
Christian Haverkamp
4Institute for Digitalization in Medicine, Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg, Germany
Daniel Boehringer
3Eye Center, Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg, Germany
Joerg J Meerpohl
1Institute for Evidence in Medicine, Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg, Germany
2Cochrane Germany, Cochrane Germany Foundation, Freiburg, Germany

Article usage
Posted July 16, 2024.
Exploring the potential of Claude 2 for risk of bias assessment: Using a large language model to assess randomized controlled trials with RoB 2
Angelika Eisele-Metzger, Judith-Lisa Lieberum, Markus Toews, Waldemar Siemens, Felix Heilmeyer, Christian Haverkamp, Daniel Boehringer, Joerg J Meerpohl
medRxiv 2024.07.16.24310483; doi: https://doi.org/10.1101/2024.07.16.24310483
Exploring the potential of Claude 2 for risk of bias assessment: Using a large language model to assess randomized controlled trials with RoB 2
Angelika Eisele-Metzger, Judith-Lisa Lieberum, Markus Toews, Waldemar Siemens, Felix Heilmeyer, Christian Haverkamp, Daniel Boehringer, Joerg J Meerpohl
medRxiv 2024.07.16.24310483; doi: https://doi.org/10.1101/2024.07.16.24310483
Subject Area
Subject Areas
- Addiction Medicine (349)
- Allergy and Immunology (668)
- Allergy and Immunology (668)
- Anesthesia (181)
- Cardiovascular Medicine (2648)
- Dermatology (223)
- Emergency Medicine (399)
- Epidemiology (12228)
- Forensic Medicine (10)
- Gastroenterology (759)
- Genetic and Genomic Medicine (4103)
- Geriatric Medicine (387)
- Health Economics (680)
- Health Informatics (2657)
- Health Policy (1005)
- Hematology (363)
- HIV/AIDS (851)
- Medical Education (399)
- Medical Ethics (109)
- Nephrology (436)
- Neurology (3882)
- Nursing (209)
- Nutrition (577)
- Oncology (2030)
- Ophthalmology (585)
- Orthopedics (240)
- Otolaryngology (306)
- Pain Medicine (250)
- Palliative Medicine (75)
- Pathology (473)
- Pediatrics (1115)
- Primary Care Research (452)
- Public and Global Health (6527)
- Radiology and Imaging (1403)
- Respiratory Medicine (871)
- Rheumatology (409)
- Sports Medicine (342)
- Surgery (448)
- Toxicology (53)
- Transplantation (185)
- Urology (165)